Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-Stage Kidney Failure Patients - Related Studies

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-Stage Kidney Failure Patients

This study is ongoing, but not recruiting participants.

Study NCT00426712. Last updated on January 22, 2008. Information provided by Dynavax Technologies Corporation

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Hepatitis B

2	Additional conditions recognized in this trial
		Hepatitis
		Kidney Failure

3	More general conditions related to this trial
		Digestive System Diseases
		DNA Virus Infections
		Hepadnaviridae Infections
		Hepatitis, Viral, Human
		Kidney Diseases
		Liver Diseases
		Renal Insufficiency
		Urologic Diseases
		Virus Diseases

4	Interventions listed in this trial
		Hepatitis B Vaccine (Recombinant)

5	Sponsors listed in this trial
		Dynavax Technologies Corporation